Bio-rad Laboratories Stock News

The HbA1c Testing Device Market Report 2021-2027 provides global market size, regional and national level market size, market segment growth, market share, competitive landscape, sales analysis, influence of domestic and global market participants, and value chain Detailed analysis of optimization,

The Hemato oncology testing report published by Data Bridge Market research is the representation of data and analysis of the market. It gives detailed analysis of the current market scenario and a market forecast till 2028. The data

Overview of the Global Viral Hepatitis and Retrovirus Diagnostic Tests Market: Market survey conducted in Viral Hepatitis and Retrovirus Diagnostic Tests Market research report helps to find out important information about the buyer personas, target audience, current customers, market, competition, and more

Data Bridge Market research presents the top quality and comprehensive Viral Hepatitis and Retrovirus Diagnostic Tests research report which provides clear insights into market dynamics and prospects the whole market including global production, revenue forecast, value and volume. This

As market research reports are attaining immense importance in this swiftly transforming market place, DBMR team endows with the top notch Biotechnology market research reports in a way that is anticipated. It all-inclusively estimates general market conditions, the growth prospects

Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.

Electroporation Instruments Market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2021-2028). The research presents a complete assessment of the market and contains Future trend, Current Growth Factors,

Denali Advisors LLC lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 12.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 900 shares of the medical research companys stock after acquiring an additional 100 shares during the quarter. Denali Advisors LLCs holdings []

Parametric Portfolio Associates LLC boosted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 5.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 73,797 shares of the medical research companys stock after buying an additional 3,785 shares during the period. Parametric Portfolio []

Various key players are discussed in this report such as Philips Healthcare, Becton, Dickinson & Company, Abbott Laboratories, Thermo Fisher Scientific Inc., Biomérieux, Alere Inc, Bio-Rad Laboratories, Inc., Cosmed, and Seegene Inc Various key players are discussed in this report such as Philips Healthcare, Becton, Dickinson & Company, Abbott Laboratories, Thermo Fisher Scientific Inc., Biomérieux, Alere Inc, Bio-Rad Laboratories, Inc., Cosmed, and Seegene Inc

Industrial Growth Forecast Report Cardiac Biomarkers Market 2021-2028: The Market Report provides Insightful information to the clients enhancing their basic leadership capacity identified with the Cardiac Biomarkers Market business, including market dynamics, segmentation, competition, and regional growth. The strategy of

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $752.95 and last traded at $752.95, with a volume of 7 shares. The stock had previously closed at $752.95. The firm has a market cap of $22.53 billion, a P/E ratio of 45.72 and []

Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP Annette Tumolo sold 1,546 shares of Bio-Rad Laboratories stock in a transaction dated Thursday, November 11th. The shares were sold at an average price of $749.00, for a total value of $1,157,954.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this []

Biotest Aktiengesellschaft (ETR:BIO)s share price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as 44.00 ($51.76) and last traded at 43.70 ($51.41), with a volume of 2525 shares traded. The stock had previously closed at 43.30 ($50.94). The company has a debt-to-equity ratio of 122.54, a quick []

The Latest survey report on Global Point-of-Care or Rapid Testing Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, Point-of-Care or Rapid Testing organizations have the dual challenge of increasing